Welcome to Dilafor

Dilafor develops pharmaceutical products from heparin derivatives with low anticoagulant activity.
The company has a balanced product portfolio representing some highly promising ideas and innovations. Each of our projects addresses an important and unfulfilled medical need.

All our drug development projects are based on the use of Low Anticoagulant Heparin (LAH). Although standard heparin has numerous biological functions, its potential development as a treatment for indications other than those currently approved is limited by its anticoagulative properties. Dilafor has produced several forms of LAH.
Two products are presently in clinical trials; DF01, for the prevention and normalization of protracted labor, is currently in clinical development and results from a recently completed Phase II clinical trial will be presented during 2009. DF02, for the treatment of severe malaria, is presently in clinical development Phase I. An ongoing Phase I clinical trial will be completed during 2009, and will be followed by a proof of concept trial in Phase II.

Further New Chemical Entities similar to DF01 and DF02 are being developed for other indications.